First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world
Datamatics will automate the Medication Administration Record process by integrating its intelligent automation products, TruBot and TruCap+
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Subscribe To Our Newsletter & Stay Updated
